```html

Kappa Light Chain Amyloidosis (AL Amyloidosis)

Overview

AL amyloidosis (amyloid light‑chain amyloidosis) is a rare, progressive disease in which an abnormal protein called a **light chain**—produced by plasma cells in the bone marrow—misfolds and deposits as rigid, insoluble fibrils in organs and tissues. When the light chain is of the **kappa (κ) subtype**, the condition is often referred to as “kappa light chain amyloidosis.” The deposits interfere with normal organ function and can be life‑threatening if not treated promptly.

• Who it affects: Adults, most often between 55‑75 years of age. Slight male predominance (≈1.3 : 1). <sup>[1]</sup>
• Prevalence: Approximately 4–6 cases per million people per year in the United States; kappa‑type accounts for roughly 30‑35 % of all AL amyloidosis cases. <sup>[2]</sup>
• Nature of disease: Systemic (multiple organs) in 70 % of cases; can also be localized (e.g., tongue, skin) but this is uncommon for κ‑type.

AL amyloidosis is a medical emergency because organ damage may progress rapidly. Early recognition and treatment (often with chemotherapy and stem‑cell transplantation) significantly improve survival—median overall survival has increased from < 2 years to > 5 years in patients who receive modern therapy. <sup>[3]</sup>

Symptoms

Symptoms depend on which organs are infiltrated. Below is a comprehensive list with brief explanations.

Cardiac (heart)

• Shortness of breath (dyspnea) on exertion or while lying flat (orthopnea).
• Peripheral edema (swelling of ankles/feet) due to heart failure.
• Fatigue & exercise intolerance from reduced cardiac output.
• Palpitations or arrhythmias—amyloid deposits can affect the conduction system.

Renal (kidneys)

• Proteinuria – foamy urine, often the first clue.
• Edema – especially in the lower extremities.
• Decreased urine output or “frothy” urine as kidney function declines.

Gastrointestinal & Hepatic

• Weight loss despite normal appetite.
• Nausea, early satiety, or feeling full quickly.
• Diarrhea or constipation – amyloid can affect the GI tract wall.
• Hepatomegaly (enlarged liver) & mild jaundice.

Nervous system

• Paresthesia (tingling) or numbness in hands/feet (peripheral neuropathy).
• Autonomic dysfunction – orthostatic hypotension, gastroparesis, urinary retention.
• Carpal tunnel syndrome – often an early clue in AL amyloidosis.

Soft tissue & Skin

• Purple‑brown bruises (purpura) around the eyes (raccoon eyes) or on the neck.
• Macroglossia – enlarged tongue; a classic but uncommon sign.
• Easy bruising due to vascular fragility.

Systemic “B” symptoms

• Fever, night sweats, unexplained weight loss – may mimic lymphoma.

Causes and Risk Factors

AL amyloidosis is not inherited. The disease stems from a clone of abnormal plasma cells in the bone marrow that over‑produce a single type of immunoglobulin light chain (kappa or lambda). The light chain misfolds, aggregates, and deposits as amyloid fibrils.

Primary causes

• Monoclonal plasma‑cell dyscrasia – similar to multiple myeloma but without the classic bone lesions.
• MGUS (Monoclonal Gammopathy of Undetermined Significance) – a precursor condition present in up to 30 % of AL amyloidosis patients.

Risk factors

• Age >55 years – the prevalence of plasma‑cell disorders rises with age.
• Male sex – modestly higher incidence.
• Family history of plasma‑cell disorders (e.g., multiple myeloma, MGUS) may increase risk, though direct inheritance of AL amyloidosis is rare.
• Chronic immune stimulation (e.g., longstanding infections, autoimmune disease) – may predispose to plasma‑cell clones.
• Exposure to certain chemicals (benzene, pesticides) – limited data, but occupational exposure has been linked to plasma‑cell neoplasms.

Diagnosis

Because symptoms are often vague, a high index of suspicion is essential. Diagnosis proceeds through three steps: (1) suspicion based on clinical signs, (2) detection of a monoclonal protein, and (3) confirmation of amyloid deposits.

1. Laboratory screening

• Serum protein electrophoresis (SPEP) & immunofixation – identifies monoclonal (M‑) protein.
• Serum free light‑chain assay – quantitative measurement of κ and λ free light chains; κ/λ ratio >1.65 (or <0.26) suggests clonal production. <sup>[4]</sup>
• Urine protein electrophoresis (UPEP) – looks for Bence‑Jones protein (light chains) in urine.
• Complete blood count, metabolic panel, cardiac biomarkers (NT‑proBNP, troponin) – assess organ involvement.

2. Tissue biopsy

Definitive diagnosis requires a specimen that shows amyloid with Congo‑red staining under polarized light (apple‑green birefringence).

• Abdominal fat‑pad aspiration – minimally invasive, positive in 70‑80 % of systemic cases.
• Organ‑specific biopsy (e.g., heart, kidney, nerve) – indicated when fat‑pad biopsy is negative but suspicion remains high.
• Immunohistochemistry or mass spectrometry – determines the amyloid type (κ‑light chain vs λ‑light chain, or other proteins).

3. Staging and organ assessment

• Cardiac staging (Mayo 2012/2020) – uses NT‑proBNP, troponin T/I, and difference between involved and uninvolved free light chains (dFLC). Stage I–IV predicts survival. <sup>[5]</sup>
• Echocardiography & cardiac MRI – detect thickened ventricular walls, “sparkling” appearance, and late gadolinium enhancement.
• Renal assessment – urine protein quantification, estimated GFR.
• Gastrointestinal endoscopy, liver ultrasound, and nerve conduction studies – when symptoms suggest involvement.

Treatment Options

Treatment aims to stop production of the pathogenic light chain, remove existing amyloid deposits when possible, and support organ function.

1. Targeted anti‑plasma‑cell therapy

• High‑dose melphalan with autologous stem‑cell transplant (ASCT) – gold‑standard for eligible patients (≤70 years, good cardiac/renal reserve). 5‑year overall survival ~60‑70 % in transplant‑eligible cohorts. <sup>[6]</sup>
• Proteasome inhibitor‑based regimens (e.g., bortezomib‑cyclophosphamide‑dexamethasone – VCD; bortezomib‑lenalidomide‑dexamethasone – VRD). Bortezomib rapidly reduces light‑chain production.
• Immunomodulatory drugs (IMiDs) – lenalidomide or pomalidomide, often combined with dexamethasone.
• Monoclonal antibodies – daratumumab (anti‑CD38) shown to achieve deep hematologic responses in AL amyloidosis (Phase II trial, 2020). <sup>[7]</sup>

2. Supportive organ‑directed care

• Heart failure therapy – loop diuretics, careful use of ACE inhibitors/ARBs, beta‑blockers (avoid in severe hypotension).
• Renal protection – ACEi/ARBs for proteinuria, avoid nephrotoxic drugs, consider early dialysis if eGFR <30 mL/min/1.73 m².
• GI symptoms – low‑fat diet, pro‑kinetics (e.g., metoclopramide), nutritional supplements.
• Neuropathy – gabapentin, duloxetine, or pregabalin; physical therapy.

3. Emerging and adjunctive therapies

• Gene‑silencing agents (e.g., patisiran, inotersen) – currently approved for transthyretin amyloidosis; trials are ongoing for AL amyloidosis.
• Anti‑amyloid antibodies – investigational drugs (e.g., 11‑1F4) aim to clear deposited fibrils.
• Bone‑marrow transplant (non‑ASCT) and CAR‑T cell therapy – experimental approaches targeting plasma‑cell clones.

4. Lifestyle and adjunct measures

• Low‑sodium diet for heart‑failure patients.
• Fluid restriction if pulmonary edema present.
• Regular aerobic activity (as tolerated) to improve functional status.
• Vaccinations – influenza, pneumococcal, COVID‑19 (especially before immunosuppressive therapy).

Living with Kappa Light Chain Amyloidosis (AL Amyloidosis)

Managing a chronic, multisystem disease involves medical care, self‑monitoring, and psychosocial support.

Daily Management Tips

1. Medication adherence – keep a pill organizer; set alarms for oral chemotherapy or steroids.
2. Monitor weight and swelling – gain >2 kg in a day or new ankle edema may signal worsening heart failure.
3. Track urine output & protein – a simple dip‑stick at home can alert you to renal deterioration.
4. Energy conservation – break tasks into small steps; rest before fatigue sets in.
5. Nutrition – high‑protein, low‑salt meals; consider a dietitian for weight‑loss or malnutrition issues.
6. Physical activity – short walks, gentle stretching, or stationary cycling; avoid overexertion.
7. Psychological health – join a support group, consider counseling; anxiety and depression are common.
8. Regular follow‑up – hematology/oncology visits every 1–3 months during active treatment, then every 3–6 months for surveillance.

Key Follow‑up Tests

• Free light‑chain assay every 1–2 months during therapy.
• NT‑proBNP and troponin every 3 months for cardiac monitoring.
• Urine protein/creatinine ratio quarterly.
• Echocardiogram annually (or sooner if symptoms change).

Prevention

Because AL amyloidosis is caused by a spontaneous plasma‑cell clone, true primary prevention is not possible. However, certain actions can reduce the chance of progression from precursor conditions (e.g., MGUS) to full‑blown disease.

• Routine health screenings for individuals over 50, especially if they have MGUS or a family history of plasma‑cell disorders.
• Avoid excessive occupational exposure to known bone‑marrow toxins (benzene, radiation).
• Maintain cardiovascular health – hypertension, diabetes, and obesity exacerbate organ damage once amyloid is present.
• Prompt treatment of underlying chronic inflammation (e.g., rheumatoid arthritis) may lower the risk of clonal plasma‑cell evolution.

Complications

If untreated or inadequately controlled, AL amyloidosis can lead to serious, sometimes irreversible complications.

• Congestive heart failure – the leading cause of death; may progress to restrictive cardiomyopathy.
• Chronic kidney disease progressing to end‑stage renal disease (ESRD) – requiring dialysis or transplantation.
• Gastrointestinal malabsorption → severe weight loss and nutritional deficiencies.
• Peripheral neuropathy – can become disabling.
• Bleeding diathesis – due to vascular fragility and factor X deficiency.
• Secondary infections – immunosuppressive treatments increase risk.
• Thromboembolic events – especially in patients with nephrotic‑range proteinuria.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “AL Amyloidosis.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/al-amyloidosis
2. American Academy of Hematology. “Epidemiology of Amyloidosis.” 2022.
3. Dispenzieri A, et al. “Survival in AL Amyloidosis in the Era of Novel Therapies.” *Blood*, 2021; 138:2043‑2054.
4. National Institutes of Health. “Serum Free Light Chain Assay.” 2020. https://www.ncbi.nlm.nih.gov/books/NBK279384/
5. Mayo Clinic Amyloidosis Staging System. “2020 Revised Staging.” *JACC*, 2020.
6. Kumar S, et al. “Autologous Stem‑Cell Transplantation for AL Amyloidosis.” *Lancet Oncology*, 2022; 23: 987‑996.
7. Dimopoulos MA, et al. “Daratumumab in AL Amyloidosis.” *NEJM*, 2020; 382:245‑254.

```